Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
AI use in schools: How districts are making sure it's used as a study aid
Recommended
How to prepare for the Fed's forthcoming interest rate cuts
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals Inc
(NQ:
MDGL
)
252.74
+4.06 (+1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
2 Top Biotech Buyout Candidates
March 31, 2024
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be...
Via
Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
March 29, 2024
Both stocks are pretty risky, but one of them more so than the other.
Via
The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
March 29, 2024
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
Via
The Motley Fool
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
March 26, 2024
This biotech just got clearance to dive into a deep ocean of a market.
Via
The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
March 15, 2024
Via
Investor Brand Network
Madrigal Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
March 22, 2024
The mid-cap biotech has succeeded where many others failed.
Via
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
March 19, 2024
Madrigal has one key advantage over its two huge potential future rivals.
Via
The Motley Fool
Exposures
Product Safety
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2024
Via
Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 15, 2024
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
Via
Benzinga
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
March 15, 2024
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease....
Via
Benzinga
Exposures
Product Safety
Why Is Geron (GERN) Stock Up 94% Today?
March 15, 2024
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing.
Via
InvestorPlace
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
March 15, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
March 15, 2024
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today.
Via
InvestorPlace
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 15, 2024
Via
Benzinga
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
March 15, 2024
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
March 15, 2024
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
March 14, 2024
Via
Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 14, 2024
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Via
Benzinga
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH
March 14, 2024
The company hopes to be the first to the finish line with a treatment for MASH.
Via
Investor's Business Daily
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
March 05, 2024
This business could be on the cusp of making medical history.
Via
The Motley Fool
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
February 23, 2024
The company might have a bright future, but is now the right time to buy shares?
Via
The Motley Fool
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
February 08, 2024
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.